Invesaro

Stocks Health care KMDA

NASDAQ · Health care

Kamada Ltd (KMDA)

Kamada Ltd reported revenue of $180.5M in fiscal 2025, up 12.1% from a year earlier. Net income was $20.2M, a net margin of 11.2%. At December 31, 2025 it held $75.5M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 11, 2026.

Revenue (FY2025)
$180.5M
+12.1% year on year
Net margin
11.2%

What Kamada Ltd does

Kamada Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KMDA.

Revenue and profit by year

Revenue
FY18: $114.5M $114.5M FY18FY19: $127.2M $127.2M FY19FY20: $133.2M $133.2M FY20FY21: $103.6M $103.6M FY21FY22: $129.3M $129.3M FY22FY23: $142.5M $142.5M FY23FY24: $161M $161M FY24FY25: $180.5M $180.5M FY25
Net income
FY18: $22.3M $22.3M FY18FY19: $22.3M $22.3M FY19FY20: $17.1M $17.1M FY20FY21: -$2.2M -$2.2M FY21FY22: -$2.3M -$2.3M FY22FY23: $8.3M $8.3M FY23FY24: $14.5M $14.5M FY24FY25: $20.2M $20.2M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$180.5M$26.2M$20.2M$0.35n/a
2024$161M$20.1M$14.5M$0.25n/a
2023$142.5M$10.1M$8.3M$0.15n/a
2022$129.3M$4.5M-$2.3M-$0.05n/a
2021$103.6M-$696K-$2.2M-$0.05n/a
2020$133.2M$19.2M$17.1M$0.38n/a

Latest SEC filings

What Kamada Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 17, 2026
    Foreign issuer update 6-K
  2. September 10, 2026
    Foreign issuer update 6-K
  3. September 9, 2026
    Form F-3 filing F-3
  4. September 3, 2026
    Foreign issuer update 6-K
  5. August 20, 2026
    Passive stake changed SCHEDULE 13G/A
  6. August 17, 2026
    Foreign issuer update 6-K
  7. August 12, 2026
    Foreign issuer update 6-K
  8. August 5, 2026
    Foreign issuer update 6-K
  9. August 5, 2026
    Foreign issuer update 6-K
  10. July 20, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 25, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about KMDA

What does Kamada Ltd do?

Kamada Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KMDA.

Is Kamada Ltd profitable?

Yes. In fiscal 2025 it reported net income of $20.2M on revenue of $180.5M, a net margin of 11.2%.

How much revenue does Kamada Ltd make?

In fiscal 2025 Kamada Ltd reported revenue of $180.5M. That is 12.1% more than a year earlier.

When did Kamada Ltd last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 11, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from September 25, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
AZN
Astrazeneca PLC

Follow KMDA

Get an email when Kamada Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow KMDA: get an email when it files

Where the numbers come from

Financial figures are the values Kamada Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.